Arrhythmogenic Cardiomyopathy
Cardiovascular
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
Rhythm PharmaceuticalsTideglusib
Lexeo TherapeuticsLX2020
Clinical Trials (2)
Total enrollment: 10 patients across 2 trials
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Start: Mar 2025Est. completion: Jul 2027
Phase 2Recruiting
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
Start: Feb 2024Est. completion: Mar 202710 patients
Phase 1/2Active Not Recruiting
Related Jobs in Cardiovascular
Embedded Software and System Test Engineer (H/F)
Cardiawave
Levallois-Perret, France (Hybrid)
Just now
Territory Sales Manager - Iowa / Nebraska
HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
22h ago
From $150K/yr
Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90
Johnson & Johnson
Issy-les-Moulineaux, France
23h ago
Trainee Technical Specialist
Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
23h ago
Regional Sales Specialist (Orange County / Long Beach, CA) - Johnson & Johnson MedTech, Electrophysiology
Johnson & Johnson
Irvine, California, United States of America
23h ago
$100K - $135K/yr
Clinical Consultant
Johnson & Johnson
North Ryde, New South Wales, Australia
23h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 10 patients
2 companies competing in this space